Dr Reddy’s Laboratories has received Establishment Inspection Report (EIR) from the US Food & Drug Administration (USFDA) for its API manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh.
“The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is closed,” the Hyderabad-based company said in a release.
The company’s scrip lost 0.42 per cent on the Bombay Stock Exchange on Friday to end at ₹6669.75
This is a Premium article available exclusively to our subscribers.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
TheHindu Businessline operates by its editorial values to provide you quality journalism.